Developer docs
API playgroundTry for free, no card

Search company profiles

Mobilise-D

Full company profile

uuid0035v7d

Namestring
Mobilise-D
Legal namestring
Mobilise-D
Websiteurl
mobilise-d.eu
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Mobilise-D is a European research consortium, not a commercial company, that was formed in 2019 to produce validated Digital Mobility Outcomes (DMOs) for monitoring real-world walking using body-worn inertial sensors. Between 2019 and June 2024 it operated under a €50 million grant from the IMI2 Joint Undertaking (EU Horizon 2020 plus EFPIA), coordinated by Newcastle University and Novartis, and assembled more than 300 researchers from 34 universities, hospitals, and industry partners. Its core deliverable is a set of 25 validated algorithms — including real-world walking speed as the primary outcome — extracted from accelerometer and gyroscope data and clinically validated across four patient cohorts (COPD, Parkinson's disease, multiple sclerosis, proximal femoral fracture) covering 2,382 patients at 17 EU clinical sites.

The technology stack combines a validated device-algorithm pair, the open-source MobGap Python pipeline (released on GitHub and Zenodo), and standardized technical and clinical validation protocols that achieved EMA Letters of Support in 2020 and 2021 and ongoing engagement with the FDA via pre-Letter of Intent. Outputs are openly published, including the underlying datasets from the Technical Validation Study (2020-2022) and Clinical Validation Study (2021-2024). In July 2024 Mobilise-D licensed its validated DMOs into Empatica's commercial Health Monitoring Platform, the first commercial deployment of the algorithms.

The consortium has no commercial revenue model: funding came from the IMI2 grant, outputs are publicly distributed, and there is no published pricing. Its go-to-market is community-led — patient and public advisory groups, scientific publications, open-source repositories, webinars, summer schools, and an annual conference. With the IMI project concluded in June 2024, follow-on activities are housed in two successor structures: SUSTAIN Mobilise-D (an industry-funded consortium led by Dan Rooks and Brian Caulfield that manages algorithm and data sharing) and the Mobilise-D Network (an open membership research community launched June 2024). Primary stakeholders are pharmaceutical R&D organizations, clinicians treating mobility-affecting conditions, regulatory bodies (EMA, FDA), and the patient cohorts themselves.

Short descriptiontext

Mobilise-D is a European research consortium (2019-2024) that validated 25 Digital Mobility Outcomes algorithms using body-worn sensors across 2,382 patients in four disease cohorts, serving pharmaceutical R&D, clinicians, and regulators via open-source tools and the Empatica platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital mobility outcomes, wearable gait analysis, digital health biomarkers, clinical validation studies, real-world mobility assessment
Industry3 codes
PRIMARYHLAHACAI
Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAE
Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAE
Post-Acute, Rehabilitation & Home Recovery Monitoring (PT/OT, post-surgical)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Geophysical Surveying and Mapping Services541360
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Digital Health Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1IMI Research Funding
TypeManaged Services
Description

Funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative. Mobilise-D received funding from IMI 2 Joint Undertaking under grant agreement No. 820820, with support from the European Union's Horizon 2020 research programme and EFPIA (European Federation of Pharmaceutical Industries and Associations)

mobilise-d.eu
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Mobilise-D developed and validated a set of 25 Digital Mobility Outcomes (DMOs) and associated algorithms that measure real-world walking and mobility using body-worn inertial sensors, targeting clinical trials and therapeutic development for mobility-affecting conditions. The validated algorithms, open-source analysis pipeline (MobGap), and clinical datasets are distributed through GitHub and Zenodo, with commercial integration through Empatica's Health Monitoring Platform. Outputs were pursued for regulatory endorsement via the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Recruitment of 2,382 patients exceeding targets across four disease cohorts
+3 more records
Product overview1 text field

Mobilise-D is a research consortium and technology platform that provides validated Digital Mobility Outcomes (DMOs) for measuring real-world walking and mobility using body-worn sensors. The core product consists of 25 validated mobility outcomes and associated algorithms developed through a 5-year IMI-funded project (2019-2024). The technology portfolio includes the validated device-algorithm pair, the MobGap open-source tool, and data sharing platforms via GitHub and Zenodo. The ecosystem consists of the original Mobilise-D IMI research project, the follow-on SUSTAIN Mobilise-D consortium, and the Mobilise-D Network for ongoing collaboration and dissemination of digital mobility assessment methods.

Product and service3 records
1Digital Mobility Outcomes (DMOs)
CategoryDigital health biomarkers / clinical endpoints
Description

Validated set of algorithms and methods to measure digital mobility outcomes including real-world walking speed (RWS) as primary outcome and other mobility parameters as secondary outcomes, designed for clinical validation and regulatory endorsement. Available to pharmaceutical companies, clinical trial sponsors, and researchers developing treatments for mobility-affecting conditions.

2MobGap
CategoryOpen-source software tool
Description

Open-source tool for mobility assessment with wearable devices, enabling external researchers and industry to implement real-world mobility assessment in clinical trials and research studies.

3Mobilise-D Data Sharing Platform
CategoryData platform / research repository
Description

Open data repository providing access to comprehensive datasets from the Technical Validation Study (TVS, 2020-2022) and Clinical Validation Study (CVS, 2021-2024), including algorithms and code shared via GitHub and Zenodo for researchers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-09
Description

Strategic partnership to integrate validated Digital Mobility Outcomes (DMOs) into Empatica's Health Monitoring Platform. This partnership provides users of Empatica's wearables access to 25 validated mobility outcomes, addressing the demand for high-quality digital measures in clinical trials and therapeutic development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-12
Description

Collaboration agreement to advance the use of digital health technologies in clinical trials. Focus areas include sharing learning from regulatory interactions, verification and validation of digital tools, patient-centered outcome measurements, and development of open-source platforms. C-Path is an independent nonprofit public-private partnership with the FDA.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-20
Description

Strategic partnership to accelerate translation of research into clinical practice. Aims to bring research and clinical studies closer to patients and the public, with focus on improving mobility assessment in Parkinson's disease trials and patient care.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration agreement as part of Mobilise-D's strategic collaboration policy to extend outreach and transition to sustainability through enhanced communication and long-lasting relationships.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-11-15
Description

Partnership using the Voice Global platform for Patient and Public Involvement and Engagement (PPIE) activities. Enables organization of research opportunities, communication, and discussion forums including the Patient and Public Advisory Group (PPAG) and Patient Forum.

6IDEA-FAST
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-02-12
Description

Collaboration between two EU IMI projects to strengthen research and development of digital biomarkers. Joint efforts in ethics, data-sharing, regulatory approaches, dissemination activities, creation of a Digital Health Academy, and working with target populations.

mobilise-d.eu
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Koneksa Health develops validated digital biomarkers from wearable sensors for use as clinical trial endpoints across multiple therapeutic areas. It is a direct peer to Mobilise-D because both focus on generating regulatory-grade evidence for wearable-derived endpoints in chronic disease populations.

2Biofourmis
TypeDirect peer
Description

Biofourmis builds a remote patient monitoring and digital biomarker platform used in clinical trials and care delivery for chronic conditions. It is a direct peer to Mobilise-D in producing wearable-derived digital biomarkers and RPM analytics for pharmaceutical sponsors.

TypeDirect peer
Description

APDM develops validated wearable sensors and mobility outcomes (e.g., Opal sensors, Mobility Lab) widely used in Parkinson's, MS, and frailty research. It is a direct peer to Mobilise-D in wearable mobility assessment across the same neurological and chronic disease populations.

4IXICO
TypeDirect peer
Description

IXICO provides digital analytics and biomarker services for neurodegenerative disease trials, with growing work in digital mobility outcomes for Parkinson's and similar indications. It is a direct peer to Mobilise-D in academic-grade digital biomarker analytics serving pharma clinical development.

TypeDirect peer
Description

ActiGraph designs and manufactures wearable actigraphy and inertial sensor hardware, plus the CentrePoint software platform used in clinical trials and academic research. It is a direct peer to Mobilise-D in providing validated body-worn sensors and analytics for real-world mobility and activity assessment.

TypeDirect peer
Description

VivoSense develops and qualifies digital endpoints and wearable sensor algorithms for clinical trials, with deep regulatory engagement with FDA and EMA. It is a direct peer to Mobilise-D in turning real-world wearable sensor data into accepted regulatory endpoints across chronic disease indications.

TypeDirect peer
Description

Evidation Health measures real-world health outcomes using consumer wearables and connected sensors, and partners with pharma on digital endpoint development. It is a direct peer to Mobilise-D in generating evidence-based digital measures from continuous wearable data for clinical research.

TypeBroad incumbent
Description

Medidata provides the industry's leading clinical trial data platform and is expanding into sensor and wearable-derived endpoint capture. It is a broad incumbent peer to Mobilise-D as a sponsor-facing platform that can ingest and operationalize competing mobility endpoints.

TypeBroad incumbent
Description

ICON is a global CRO with embedded digital health, wearables, and decentralized trial capabilities (including former PRA Health and Symphony Clinical Research). It is a broad incumbent peer to Mobilise-D because it can operationalize — or compete with — validated digital mobility endpoints across multi-trial programs.

TypeBroad incumbent
Description

Clario is a large clinical trial technology vendor offering endpoint collection including wearables, eCOA, and imaging. It is a broad incumbent peer to Mobilise-D because it integrates competing wearable-derived mobility endpoints (via its APDM acquisition) into commercial trial delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mobilise-D

Digital Health Technologymobilise-d.eu

Mobilise-D is a European research consortium (2019-2024) that validated 25 Digital Mobility Outcomes algorithms using body-worn sensors across 2,382 patients in four disease cohorts, serving pharmaceutical R&D, clinicians, and regulators via open-source tools and the Empatica platform.

What Mobilise-D does

Mobilise-D is a European research consortium, not a commercial company, that was formed in 2019 to produce validated Digital Mobility Outcomes (DMOs) for monitoring real-world walking using body-worn inertial sensors. Between 2019 and June 2024 it operated under a €50 million grant from the IMI2 Joint Undertaking (EU Horizon 2020 plus EFPIA), coordinated by Newcastle University and Novartis, and assembled more than 300 researchers from 34 universities, hospitals, and industry partners. Its core deliverable is a set of 25 validated algorithms — including real-world walking speed as the primary outcome — extracted from accelerometer and gyroscope data and clinically validated across four patient cohorts (COPD, Parkinson's disease, multiple sclerosis, proximal femoral fracture) covering 2,382 patients at 17 EU clinical sites.

The technology stack combines a validated device-algorithm pair, the open-source MobGap Python pipeline (released on GitHub and Zenodo), and standardized technical and clinical validation protocols that achieved EMA Letters of Support in 2020 and 2021 and ongoing engagement with the FDA via pre-Letter of Intent. Outputs are openly published, including the underlying datasets from the Technical Validation Study (2020-2022) and Clinical Validation Study (2021-2024). In July 2024 Mobilise-D licensed its validated DMOs into Empatica's commercial Health Monitoring Platform, the first commercial deployment of the algorithms.

The consortium has no commercial revenue model: funding came from the IMI2 grant, outputs are publicly distributed, and there is no published pricing. Its go-to-market is community-led — patient and public advisory groups, scientific publications, open-source repositories, webinars, summer schools, and an annual conference. With the IMI project concluded in June 2024, follow-on activities are housed in two successor structures: SUSTAIN Mobilise-D (an industry-funded consortium led by Dan Rooks and Brian Caulfield that manages algorithm and data sharing) and the Mobilise-D Network (an open membership research community launched June 2024). Primary stakeholders are pharmaceutical R&D organizations, clinicians treating mobility-affecting conditions, regulatory bodies (EMA, FDA), and the patient cohorts themselves.

Mobilise-D firmographics

Firmographics
Name
Mobilise-D
Legal name
Mobilise-D
Website
https://mobilise-d.eu
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Mobilise-D is a European research consortium (2019-2024) that validated 25 Digital Mobility Outcomes algorithms using body-worn sensors across 2,382 patients in four disease cohorts, serving pharmaceutical R&D, clinicians, and regulators via open-source tools and the Empatica platform.
Ownership category
akta.pro rank

Mobilise-D industry classification

Industry
Product category
Digital Health Technology
NAICS
Geophysical Surveying and Mapping Services (541360)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHACAI
Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAE
Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAE
Post-Acute, Rehabilitation & Home Recovery Monitoring (PT/OT, post-surgical)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Digital mobility outcomes
  • Wearable gait analysis
  • Digital health biomarkers
  • Clinical validation studies
  • Real-world mobility assessment

Mobilise-D business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. IMI Research Funding: Funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative. Mobilise-D received funding from IMI 2 Joint Undertaking under grant agreement No. 820820, with support from the European Union's Horizon 2020 research programme and EFPIA (European Federation of Pharmaceutical Industries and Associations)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Mobilise-D product offering

Product offering

Core offering

Mobilise-D developed and validated a set of 25 Digital Mobility Outcomes (DMOs) and associated algorithms that measure real-world walking and mobility using body-worn inertial sensors, targeting clinical trials and therapeutic development for mobility-affecting conditions. The validated algorithms, open-source analysis pipeline (MobGap), and clinical datasets are distributed through GitHub and Zenodo, with commercial integration through Empatica's Health Monitoring Platform. Outputs were pursued for regulatory endorsement via the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

Product overview

Mobilise-D is a research consortium and technology platform that provides validated Digital Mobility Outcomes (DMOs) for measuring real-world walking and mobility using body-worn sensors. The core product consists of 25 validated mobility outcomes and associated algorithms developed through a 5-year IMI-funded project (2019-2024). The technology portfolio includes the validated device-algorithm pair, the MobGap open-source tool, and data sharing platforms via GitHub and Zenodo. The ecosystem consists of the original Mobilise-D IMI research project, the follow-on SUSTAIN Mobilise-D consortium, and the Mobilise-D Network for ongoing collaboration and dissemination of digital mobility assessment methods.

Differentiator

Problem solved

Functional benefit

Products and services

  • Digital Mobility Outcomes (DMOs) Validated set of algorithms and methods to measure digital mobility outcomes including real-world walking speed (RWS) as primary outcome and other mobility parameters as secondary outcomes, designed for clinical validation and regulatory endorsement. Available to pharmaceutical companies, clinical trial sponsors, and researchers developing treatments for mobility-affecting conditions.
  • MobGap Open-source tool for mobility assessment with wearable devices, enabling external researchers and industry to implement real-world mobility assessment in clinical trials and research studies.
  • Mobilise-D Data Sharing Platform Open data repository providing access to comprehensive datasets from the Technical Validation Study (TVS, 2020-2022) and Clinical Validation Study (CVS, 2021-2024), including algorithms and code shared via GitHub and Zenodo for researchers.

Quantifiable outcome

  • Recruitment of 2,382 patients exceeding targets across four disease cohorts
  • +3 more outcomes

Companies that use Mobilise-D

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Mobilise-D technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature4 records

Mobilise-D partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • EmpaticacoreTechnology or Integration · 9 July 2024Strategic partnership to integrate validated Digital Mobility Outcomes (DMOs) into Empatica's Health Monitoring Platform. This partnership provides users of Empatica's wearables access to 25 validated mobility outcomes, addressing the demand for high-quality digital measures in clinical trials and therapeutic development.
  • Critical Path Institute (C-Path)coreStrategic or Co-development Partner · 12 December 2022Collaboration agreement to advance the use of digital health technologies in clinical trials. Focus areas include sharing learning from regulatory interactions, verification and validation of digital tools, patient-centered outcome measurements, and development of open-source platforms. C-Path is an independent nonprofit public-private partnership with the FDA.
  • Cure Parkinson's UKcoreStrategic or Co-development Partner · 20 September 2022Strategic partnership to accelerate translation of research into clinical practice. Aims to bring research and clinical studies closer to patients and the public, with focus on improving mobility assessment in Parkinson's disease trials and patient care.
  • NEURONETsupportingStrategic or Co-development Partner · 1 January 2022Collaboration agreement as part of Mobilise-D's strategic collaboration policy to extend outreach and transition to sustainability through enhanced communication and long-lasting relationships.
  • Voice GlobalsupportingStrategic or Co-development Partner · 15 November 2021Partnership using the Voice Global platform for Patient and Public Involvement and Engagement (PPIE) activities. Enables organization of research opportunities, communication, and discussion forums including the Patient and Public Advisory Group (PPAG) and Patient Forum.
  • IDEA-FASTsupportingStrategic or Co-development Partner · 12 February 2021Collaboration between two EU IMI projects to strengthen research and development of digital biomarkers. Joint efforts in ethics, data-sharing, regulatory approaches, dissemination activities, creation of a Digital Health Academy, and working with target populations.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Mobilise-D competitors and assessment

Company assessment

Direct peers

  • Koneksa Health: Koneksa Health develops validated digital biomarkers from wearable sensors for use as clinical trial endpoints across multiple therapeutic areas. It is a direct peer to Mobilise-D because both focus on generating regulatory-grade evidence for wearable-derived endpoints in chronic disease populations.
  • Biofourmis: Biofourmis builds a remote patient monitoring and digital biomarker platform used in clinical trials and care delivery for chronic conditions. It is a direct peer to Mobilise-D in producing wearable-derived digital biomarkers and RPM analytics for pharmaceutical sponsors.
  • APDM Wearable Technologies (a Clario company): APDM develops validated wearable sensors and mobility outcomes (e.g., Opal sensors, Mobility Lab) widely used in Parkinson's, MS, and frailty research. It is a direct peer to Mobilise-D in wearable mobility assessment across the same neurological and chronic disease populations.
  • IXICO: IXICO provides digital analytics and biomarker services for neurodegenerative disease trials, with growing work in digital mobility outcomes for Parkinson's and similar indications. It is a direct peer to Mobilise-D in academic-grade digital biomarker analytics serving pharma clinical development.
  • ActiGraph: ActiGraph designs and manufactures wearable actigraphy and inertial sensor hardware, plus the CentrePoint software platform used in clinical trials and academic research. It is a direct peer to Mobilise-D in providing validated body-worn sensors and analytics for real-world mobility and activity assessment.
  • VivoSense: VivoSense develops and qualifies digital endpoints and wearable sensor algorithms for clinical trials, with deep regulatory engagement with FDA and EMA. It is a direct peer to Mobilise-D in turning real-world wearable sensor data into accepted regulatory endpoints across chronic disease indications.
  • Evidation Health: Evidation Health measures real-world health outcomes using consumer wearables and connected sensors, and partners with pharma on digital endpoint development. It is a direct peer to Mobilise-D in generating evidence-based digital measures from continuous wearable data for clinical research.

Broad incumbents

  • Medidata (Dassault Systèmes): Medidata provides the industry's leading clinical trial data platform and is expanding into sensor and wearable-derived endpoint capture. It is a broad incumbent peer to Mobilise-D as a sponsor-facing platform that can ingest and operationalize competing mobility endpoints.
  • ICON plc: ICON is a global CRO with embedded digital health, wearables, and decentralized trial capabilities (including former PRA Health and Symphony Clinical Research). It is a broad incumbent peer to Mobilise-D because it can operationalize — or compete with — validated digital mobility endpoints across multi-trial programs.
  • Clario: Clario is a large clinical trial technology vendor offering endpoint collection including wearables, eCOA, and imaging. It is a broad incumbent peer to Mobilise-D because it integrates competing wearable-derived mobility endpoints (via its APDM acquisition) into commercial trial delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Mobilise-D social profiles

Digital presence

Mobilise-D financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mobilise-D leadership team

Management profile

Number of profiles

Profiles14 records

Mobilise-D subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Mobilise-D funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mobilise-D M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mobilise-D

What does Mobilise-D do?

Mobilise-D developed and validated a set of 25 Digital Mobility Outcomes (DMOs) and associated algorithms that measure real-world walking and mobility using body-worn inertial sensors, targeting clinical trials and therapeutic development for mobility-affecting conditions. The validated algorithms, open-source analysis pipeline (MobGap), and clinical datasets are distributed through GitHub and Zenodo, with commercial integration through Empatica's Health Monitoring Platform. Outputs were pursued for regulatory endorsement via the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

Is Mobilise-D a public or private company?

Mobilise-D is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Mobilise-D founded?

Mobilise-D was founded in 2019. It employs 1 to 10 people.

How does Mobilise-D make money?

One revenue line is on record: IMI Research Funding.

Who are Mobilise-D's main competitors?

Direct peers on record are Koneksa Health, Biofourmis, APDM Wearable Technologies (a Clario company), IXICO, ActiGraph, VivoSense and Evidation Health. Broad incumbents are Medidata (Dassault Systèmes), ICON plc and Clario.

Does Mobilise-D have an API?

No public API is recorded for Mobilise-D.

What industry is Mobilise-D in?

Mobilise-D's product category is Digital Health Technology. Its primary akta.pro industry code is HLAHACAI, Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking), with a secondary code of HLACAPAE, Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT). Its NAICS code is 541360 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals